Immunotherapy with depigmented-polymerized mixed tree pollen extract: A clinical trial and responder analysis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 65, Issue 12, 2010, Pages 1614-1621

  Pfaar, O ^a   Robinson, D S ^b   Sager, A ^c   Emuzyte, R ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Laboratorios LETI SL   (Spain)

^c LETI Pharma GmbH   (Germany)

^d VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Allergic rhinitis; Allergoid; Depigmented polymerized allergen extract; Specific subcutaneous immunotherapy (SCIT); Tree pollen

Indexed keywords

ALNUS GLUTINOSA EXTRACT; BETULA ALBA EXTRACT; CORYLUS AVELLANA EXTRACT; DEPIGOID; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; PLACEBO; POLLEN EXTRACT; UNCLASSIFIED DRUG;

ADULT; AGED; ALNUS GLUTINOSA; ARTICLE; ASTHMA; BETULA ALBA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORYLUS AVELLANA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FEMALE; HUMAN; IMMUNOTHERAPY; LACRIMATION DISORDER; MALE; MEDICINAL PLANT; NASAL PRURITUS; NOSE CONGESTION; OCULAR PRURITUS; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; RHINORRHEA; SELF REPORT; SENSITIZATION; SNEEZING; URTICARIA;

ADULT; ALLERGENS; AREA UNDER CURVE; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; PLANT EXTRACTS; POLLEN; RHINITIS, ALLERGIC, SEASONAL; ROC CURVE; TREES;

EID: 78349299047     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2010.02413.x     Document Type: Article

References (35)

1. Bauchau V, Durham SR,. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. 1. Allergy 2005; 60: 350 -353.
2. Abramson MJ, Puy RM, Weiner JM,. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003;(4): CD001186.
3. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S,. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; Jan 24;(1):CD001936.
4. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E,. Standards for practical allergen-specific immunotherapy. Allergy 2006; 61 (Suppl. 82): 1 -20.
5. Bousquet J, Demoly P,. Specific immunotherapy-an optimistic future. Allergy 2006; 61: 1155 -1158.
6. Durham SR, Walker SM, Varga EM, Jacobson MR, OBrien F, Noble W, etal. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468 -475.
7. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, etal. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62: 943 -948.
8. Arvidsson MB, Lowhagen O, Rak S,. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002; 109: 777 -783.
9. Bodtger U, Poulsen LK, Jacobi HH, Malling HJ,. The safety and efficacy of subcutaneous birch pollen immunotherapy -a one-year, randomised, double-blind, placebo-controlled study. Allergy 2002; 57: 297 -305.
10. Jacobsen L, Nuchel-Petersen B, Wihl JA, Lowenstein H, Ipsen H,. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long term (6year) follow-up. Allergy 1997; 52: 914 -920.
11. Petersen BN, Janniche H, Munch EP, Wihl JA, Böwadt H, Ipsen H, etal. Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988; 43: 353 -362.
12. Wihl JA, Ipsen H, Petersen BN, Munch EP, Janniche H, Løwenstein H,. Immunotherapy with partially purified and standardized tree pollen extracts. II. Results of skin prick tests and nasal provocation tests from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988; 43: 363 -369.
13. Möller C, Dreborg S,. Cross-reactivity between deciduous trees during immunotherapy. I. In vivo results. Clin Allergy 1986; 16: 135 -143.
14. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA,. Survey of fatalities from skin testing and immunotherapy 1985-1989. J Allergy Clin Immunol 1993; 92: 6 -15.
15. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, Bukantz SC,. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001; 87: 47 -55.
16. Marsh DG,. Preparation and properties of allergoids, derived from native pollen allergens by mild formalin treatment. Int Arch Allergy Appl Immunol. 1971; 41: 199 -215.
17. Creticos PS, Van Metre TE, Mardiney MR, Rosenberg GL, Norman PS, Adkinson NF Jr,. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 1984; 73: 94 -104.
18. Middleton E Jr, Kandaswami C,. Effects of flavonoids on immune and inflammatory cell functions. Biochem Pharmacol 1992; 43: 1167 -1179.
19. Colás C, Monzón S, Venturini M, Lezaun A,. A double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. J Allergy Clin Immunol 2006; 117: 810 -816.
20. Ameal A, Vega-Chicote JM, Fernandez S, Miranda A, Carmona MJ, Rondon MC, etal. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 2005; 60: 1178 -1183.
21. Casanovas M, Martin R, Jimenez C, Caballero R, Fernandez-Caldas E,. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerised allergen extracts. Int Arch Allergy Immunol 2006; 139: 153 -158.
22. Garcia-Robaina JC, Sanchez I, De La Torre F, Fernandez-Caldas E, Casanovas M,. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 2006; 118: 1026 -1032.
23. Casanovas M, Martin R, Jimenez C, Caballero R, Fernandez-Caldas E,. Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerised allergen extracts. Clin Exp Allergy 2007; 37: 434 -440.
24. World Medical Association Declaration Of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 59th WMA General Assembly, Seoul, October 2008.
25. Malling H, Weeke B,. Position paper: immunotherapy. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy 1993; 48: 7 -35.
26. Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gerstner B, etal. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 2004; 59: 973 -979.
27. El Shami AS, Alaba O,. Liquid-phase in vitro allergen specific IgE assay with in situ immobilization. Adv Biosci 1989; 74: 191 -201.
28. Mauro M, Russello M, Incorvaia C, Gazzola GB, Di Cara G, Frati F,. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Eur Ann Allergy Clin Immunol 2007; 39: 119 -122.
29. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ,. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004; 59: 45 -53. (Pubitemid 38167951)
30. Malling HJ,. Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 53: 461 -472.
31. Di Lorenzo G, Mansueto P, Pacor ML, Rizzo M, Castello F, Martinelli N, etal. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol 2009; 123: 1103 -1110.
32. Sager A, Renner BG,. Safety aspects and course of allergen-specific immunotherapy with a depigmented, polymerised allergen extract. Allergo J 2004; 13: 386 -391.
33. Pfaar O, Klimek L, Sager A, Bräutigam M,. Safety of a depigmented, polymerized vaccine for the treatment of allergic rhinoconjunctivitis and allergic asthma. Am J Rhinol Allergy 2010; 24: 220 -225.
34. Durham SR, Till SJ,. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998; 102: 157 -164.
35. Rak S, Höiby A, Strand V, Sager A,. Immunological changes in patients with rhinoconjunctivitis following a 2year specific immunotherapy treatment with Depigoid birch pollen extract in a double blind placebo controlled study. Allergy 2008; 63 (Suppl.88): 237. (abstract).